Over the last 7 days, the United States market has dropped 1.1%, yet it remains up by 9.1% over the past year with earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks that can capitalize on these positive earnings projections is crucial for investors seeking opportunities in a dynamic and evolving sector.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 26.38% | 39.09% | ★★★★★★ |
| Ardelyx | 20.78% | 59.46% | ★★★★★★ |
| Travere Therapeutics | 26.41% | 64.47% | ★★★★★★ |
| Blueprint Medicines | 21.36% | 61.45% | ★★★★★★ |
| TG Therapeutics | 26.46% | 38.75% | ★★★★★★ |
| Alnylam Pharmaceuticals | 23.65% | 61.11% | ★★★★★★ |
| AVITA Medical | 27.28% | 60.66% | ★★★★★★ |
| Alkami Technology | 20.54% | 76.67% | ★★★★★★ |
| Ascendis Pharma | 35.16% | 60.26% | ★★★★★★ |
| Lumentum Holdings | 21.59% | 110.32% | ★★★★★★ |
Click here to see the full list of 235 stocks from our US High Growth Tech and AI Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
ARS Pharmaceuticals (NasdaqGM:SPRY)
Simply Wall St Growth Rating: ★★★★★☆
Overview: ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions, with a market cap of $1.41 billion.
Operations: ARS Pharmaceuticals specializes in creating and marketing therapies for acute allergic responses. The company operates with a market capitalization of approximately $1.41 billion.
ARS Pharmaceuticals has shown a dynamic shift in its market approach, particularly with the recent FDA approval and commercialization of neffy, a needle-free epinephrine nasal spray. This innovation not only diversifies their product line but also taps into a critical need for safer, more accessible treatments for life-threatening allergic reactions. The company's strategic partnership with ALK-Abello to target up to 9,000 pediatricians underscores its aggressive marketing and expansion strategy. Despite a significant net loss reported in Q1 2025 of $33.94 million, ARS Pharmaceuticals is poised for growth with expected revenue increases driven by neffy's adoption and potential market penetration during the critical back-to-school season.
- Unlock comprehensive insights into our analysis of ARS Pharmaceuticals stock in this health report.
Explore historical data to track ARS Pharmaceuticals' performance over time in our Past section.
CyberArk Software (NasdaqGS:CYBR)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: CyberArk Software Ltd. is a company that specializes in developing and selling software-based identity security solutions and services across various regions globally, with a market capitalization of approximately $17.87 billion.
Operations: CyberArk Software Ltd. generates revenue primarily from its security software and services segment, amounting to $1.10 billion. The company operates in multiple regions, including the United States, Israel, and Europe.
CyberArk Software, a leader in identity security solutions, has recently demonstrated robust financial and operational growth. In Q1 2025, the company reported a significant revenue increase to $317.6 million from $221.55 million year-over-year and improved net income to $11.46 million from $5.47 million. This performance is underpinned by strategic client expansions, such as with PDS Health integrating advanced machine identity security solutions into their systems, enhancing both compliance and operational resilience against identity-centric breaches—a critical area as AI-driven identities proliferate across industries. CyberArk's forward-looking guidance anticipates continued momentum with projected annual revenues reaching up to $1.323 billion, signaling strong market demand for its comprehensive identity security platforms that now extend into securing AI agents and cloud environments.
- Click here and access our complete health analysis report to understand the dynamics of CyberArk Software.
Understand CyberArk Software's track record by examining our Past report.
BeiGene (NasdaqGS:ONC)
Simply Wall St Growth Rating: ★★★★★☆
Overview: BeiGene, Ltd. is an oncology company focused on discovering and developing cancer treatments globally, with a market cap of $25.62 billion.
Operations: The company generates revenue primarily from its pharmaceutical products, amounting to $4.18 billion.
BeiGene, amid a transformative phase, reported a remarkable rebound with Q1 2025 revenues soaring to $1.12 billion from $751.65 million the previous year, underpinned by robust sales of its flagship product BRUKINSA. This performance aligns with their optimistic full-year revenue projection ranging between $4.9 billion and $5.3 billion, reflecting sustained global market penetration especially in U.S and European sectors. Recent strategic alliances, like the one with nference to enhance B-cell cancer treatments using AI analytics, further bolster BeiGene's innovative edge in oncology research and development—critical as it transitions to BeOne Medicines aiming for broader therapeutic impacts across cancer care spectrums.
- Click here to discover the nuances of BeiGene with our detailed analytical health report.
Gain insights into BeiGene's historical performance by reviewing our past performance report.
Where To Now?
- Gain an insight into the universe of 235 US High Growth Tech and AI Stocks by clicking here.
- Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if BeiGene might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com